The pain medication treats moderate to severe acute pain and it has non-addictive properties, the first of it's kind approved by the FDA in more than 20 years.
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
The FDA removed previously issued draft guidance on diversity in clinical trials from its website without public notice or ...
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...
Journavx (suzetrigine) is said to reduce pin by "targeting a pain-signaling pathway involving sodium channels in the ...
Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.
The FDA has approved suzetrigine, a new, non-opioid medication for adults with moderate to severe acute pain.
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...